Nicotine vaccines for smoking cessation

Keyphrases

• Smoking Cessation 100%
• Nicotine Vaccine 100%
• Adverse Events 37%
• NicVAX 31%
• Placebo 25%
• Phase II Trial 18%
• Nicotine 18%
• Moderate to Severe 12%
• Vaccine Candidate 12%
• Relapse Prevention 12%
• Abstinence 12%
• Serious Adverse Events 12%
• Risk Ratio 12%
• 95% Confidence Interval 12%
• General Public 6%
• Tolerability 6%
• Withdrawal Symptoms 6%
• Tobacco 6%
• Human Subjects 6%
• Smoking Relapse 6%
• Randomized Controlled Trial 6%
• Tobacco Use 6%
• Drug Development 6%
• Cigarette 6%
• Smokers 6%
• Public Use 6%
• Pharmaceutical Companies 6%
• Treatment Duration 6%
• Vaccin 6%
• Design Requirements 6%
• No Significant Difference 6%
• External Validity 6%
• Quit Smoking 6%
• Concealment 6%
• MEDLINE 6%
• Cochrane 6%
• Embase 6%
• Quitters 6%
• Search Methods 6%
• Adult Smokers 6%
• Google 6%
• Google Scholar 6%
• Ex-smokers 6%
• Primary Outcome Measure 6%
• Selection Criteria 6%
• Active Groups 6%
• Quit Rate 6%
• Risk of Bias 6%
• Exclusion Criteria 6%
• Meeting Abstracts 6%
• PsycINFO 6%
• Flu-like 6%
• Trial Outcomes 6%
• Tobacco Addiction 6%
• Long-term Smoking 6%
• Company Website 6%
• Current Group 6%
• Search String 6%
• Discussion Section 6%
• Placebo Groups 6%
• Statistically Significant Difference 6%
• Well Tolerated 6%
• Extracted Data 6%
• Randomization Method 6%

Pharmacology, Toxicology and Pharmaceutical Science

• Nicotine Vaccine 100%
• Adverse Event 42%
• Placebo 26%
• Nicotine 15%
• Phase III and IV Trials 10%
• Drug Development 5%
• Tolerability 5%
• Randomized Controlled Trial 5%
• Withdrawal Syndrome 5%
• Tobacco Dependence 5%
• Flu Like Syndrome 5%
• Homo sapiens 5%